Role of LHPP in malignant tumor

Abstract

Li Tiantian, Chen Min, Liu Yichen, Peng Jie, Shi Xiaofeng. Role of LHPP in malignant tumor[J]. Journal of International Oncology, 2021, 48(7): 420-423.

References28

[1]	赵聪选, 于韬. 胶质瘤相关基因的挖掘及预测[J]. 国际肿瘤学杂志, 2020, 47(5):293-296. DOI: 10.3760/cma.j.cn371439-20200123-00021.
[2]	Hindupur SK, Colombi M, Fuhs SR, et al. The protein histidine phosphatase LHPP is a tumour suppressor[J]. Nature, 2018, 555(7698):678-682. DOI: 10.1038/nature26140. doi:10.1038/nature26140
[3]	Huang H, Pandya C, Liu C, et al. Panoramic view of a superfamily of phosphatases through substrate profiling[J]. Proc Natl Acad Sci U S A, 2015, 112(16):E1974-E1983. DOI: 10.1073/pnas.1423570112. doi:10.1073/pnas.1423570112
[4]	Gohla A. Do metabolic HAD phosphatases moonlight as protein phosphatases?[J]. Biochim Biophys Acta Mol Cell Res, 2019, 1866(1):153-166. DOI: 10.1016/j.bbamcr.2018.07.007. doi:10.1016/j.bbamcr.2018.07.007
[5]	Cui L, Gong X, Tang Y, et al. Relationship between the LHPP gene polymorphism and resting-state brain activity in major depressive disorder[J]. Neural Plast, 2016, 2016:9162590. DOI: 10.1155/2016/9162590.
[6]	Kestler C, Knobloch G, Tessmer I, et al. Chronophin dimerization is required for proper positioning of its substrate specificity loop[J]. J Biol Chem, 2014, 289(5):3094-3103. DOI: 10.1074/jbc.M113.536482. doi:10.1074/jbc.M113.536482
[7]	Tian Z, Yu T, Wei H, et al. Clinical value of LHPP-associated microRNAs combined with protein induced by vitamin K deficiency or antagonist-Ⅱ in the diagnosis of alpha-fetoprotein-negative hepatocellular carcinoma[J]. J Clin Lab Anal, 2020, 34(2):e23071. DOI: 10.1002/jcla.23071.
[8]	Zheng J, Dai X, Chen H, et al. Down-regulation of LHPP in cervical cancer influences cell proliferation, metastasis and apoptosis by modulating AKT[J]. Biochem Biophys Res Commun, 2018, 503(2):1108-1114. DOI: 10.1016/j.bbrc.2018.06.127. doi:10.1016/j.bbrc.2018.06.127
[9]	Li Y, Zhang X, Zhou X, et al. LHPP suppresses bladder cancer cell proliferation and growth via inactivating AKT/p65 signaling pathway[J]. Biosci Rep, 2019, 39(7): BSR20182270. DOI: 10.1042/BSR20182270.
[10]	Wu F, Chen Y, Zhu J. LHPP suppresses proliferation, migration, and invasion and promotes apoptosis in pancreatic cancer[J]. Biosci Rep, 2020, 40(3): BSR20194142. DOI: 10.1042/BSR20194142.
[11]	Hou B, Li W, Li J, et al. Tumor suppressor LHPP regulates the proliferation of colorectal cancer cells via the PI3K/AKT pathway[J]. Oncol Rep, 2020, 43(2):536-548. DOI: 10.3892/or.2019.7442.
[12]	Sun W, Qian K, Guo K, et al. LHPP inhibits cell growth and migration and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway[J]. Acta Biochim Biophys Sin (Shanghai), 2020, 52(4):382-389. DOI: 10.1093/abbs/gmaa015. doi:10.1093/abbs/gmaa015
[13]	Noorolyai S, Shajari N, Baghbani E, et al. The relation between PI3K/AKT signalling pathway and cancer[J]. Gene, 2019, 698:120-128. DOI: 10.1016/j.gene.2019.02.076. doi:S0378-1119(19)30217-3pmid:30849534
[14]	Xiao S, Yang M, Yang H, et al. miR-330-5p targets SPRY2 to promote hepatocellular carcinoma progression via MAPK/ERK signaling[J]. Oncogenesis, 2018, 7(11):90. DOI: 10.1038/s41389-018-0097-8. doi:10.1038/s41389-018-0097-8
[15]	Zhu Y, Zhou C, He Q. High miR-139-3p expression predicts a better prognosis for hepatocellular carcinoma: a pooled analysis[J]. J Int Med Res, 2019, 47(1):383-390. DOI: 10.1177/0300060518802727. doi:10.1177/0300060518802727
[16]	Ali HEA, Emam AA, Zeeneldin AA, et al. Circulating miR-26a, miR-106b, miR-107 and miR-133b stratify hepatocellular carcinoma patients according to their response to transarterial chemoembolization[J]. Clin Biochem, 2019, 65:45-52. DOI: 10.1016/j.clinbiochem.2019.01.002. doi:10.1016/j.clinbiochem.2019.01.002
[17]	Ali HEA, Abdel Hameed R, Effat H, et al. Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma[J]. Clin Res Hepatol Gastroenterol, 2017, 41(4):e51-e62. DOI: 10.1016/j.clinre.2017.06.004. doi:10.1016/j.clinre.2017.06.004
[18]	Lee Y, Dominy JE, Choi YJ, et al. Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression[J]. Nature, 2014, 510(7506):547-551. DOI: 10.1038/nature13267. doi:10.1038/nature13267
[19]	Manning BD, Toker A. AKT/PKB signaling: navigating the network[J]. Cell, 2017, 169(3):381-405. DOI: 10.1016/j.cell.2017.04.001. doi:10.1016/j.cell.2017.04.001
[20]	Chen CY, Chen J, He L, et al. PTEN: tumor suppressor and metabolic regulator[J]. Front Endocrinol (Lausanne), 2018, 9:338. DOI: 10.3389/fendo.2018.00338. doi:10.3389/fendo.2018.00338
[21]	Xia P, Xu XY. PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application[J]. Am J Cancer Res, 2015, 5(5):1602-1609. pmid:26175931
[22]	司贮元, 周旭, 朱化强, 等. 组氨酸磷酸酶LHPP对胰腺癌预后的影响[J]. 中华实验外科杂志, 2019, 36(8):1472-1474. DOI: 10.3760/cma.j.issn.1001-9030.2019.08.042.
[23]	李德馨, 刘斌, 任飞飞, 等. LHPP在人胃腺癌组织中的表达及意义[J]. 中国微生态学杂志, 2019, 31(5):544-549. DOI: 10.13381/j.cnki.cjm.201905010.
[24]	刘丹. 组氨酸磷酸酶LHPP在非小细胞肺癌中的表达及其临床意义的研究[D]. 沈阳: 中国医科大学, 2020. DOI: 10.27652/d.cnki.gzyku.2020.001364.
[25]	Zhang Q, Xiong M, Liu J, et al. Targeted nanoparticle-mediated LHPP for melanoma treatment[J]. Int J Nanomedicine, 2019, 14:3455-3468. DOI: 10.2147/IJN.S196374. doi:10.2147/IJN
[26]	Vijayakrishnan J, Kumar R, Henrion MY, et al. A genome-wide association study identifies risk loci for childhood acute lymphoblastic leukemia at 10q26.13 and 12q23.1[J]. Leukemia, 2017, 31(3):573-579. DOI: 10.1038/leu.2016.271. doi:10.1038/leu.2016.271pmid:27694927
[27]	Lesseur C, Diergaarde B, Olshan AF, et al. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer[J]. Nat Genet, 2016, 48(12):1544-1550. DOI: 10.1038/ng.3685. doi:10.1038/ng.3685pmid:27749845
[28]	Wang Z, McGlynn KA, Rajpert-De Meyts E, et al. Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor[J]. Nat Genet, 2017, 49(7):1141-1147. DOI: 10.1038/ng.3879. doi:10.1038/ng.3879

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References28

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.